Last reviewed · How we verify
Autologous CIK
At a glance
| Generic name | Autologous CIK |
|---|---|
| Sponsor | Prof. Franca Fagioli |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- CIK Cell Therapy for Relapsed or Refractory Acute B-Lymphoblastic Leukemia: Prognostic Impact on Patients With Early CAR-T Cell Dysfunction (NA)
- An Autologous NK/CIK Cell Product (PB101) in Combination With EGFR-TKI for Treating Lung Cancer (PHASE1)
- Immune Cell Therapy for Advanced Solid Tumors (PHASE1, PHASE2)
- A Clinical Study on the Safety, Tolerance, and Preliminary Efficacy of γδ-T Cell Injection in the Treatment of Advanced Bladder Cancer
- Phase II Study of Chemotherapy and PD-1 Inhibitor Combination With Autologous CIK Cell Immunotherapy to Treat Lung Cancer (PHASE2)
- The Adoptive Immunotherapy for Solid Tumors Using Modified Autologous CIK Cells (PHASE1, PHASE2)
- DCs Vaccine Combined With Cytokine-induced Killer Cells in Patients With AML (PHASE1, PHASE2)
- Hyperthermia Combined With Immunotherapy in the Treatment of Abdominal and Pelvic Malignancies or Metastases (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Autologous CIK CI brief — competitive landscape report
- Autologous CIK updates RSS · CI watch RSS
- Prof. Franca Fagioli portfolio CI